NCT00912509
Cross Linking for Treatment of Corneal Infection
A Prospective Randomized Double-masked Evaluation of Treatment Duration of the UVX System for Treating Infectious Keratitis
Price Vision Group·ClinicalTrials.gov·drugTerminated
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Infectious Keratitis
- Drug/Device/Intervention
- riboflavin
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Price Vision Group
- Location
- Indianapolis, United States of America
Timeline & enrollment
- Phase
- N/A
- Start date
- May 01, 2009
- End date
- Jun 01, 2013
- Enrollment
- 30 participants
Primary outcome
Time to Re-epithelialization
Summary
This study is comparing 45 minute and 30 minute treatment durations with the UVX corneal
 cross linking system to treat corneal infections.
ICD-10 classifications
KeratitisKeratitis, unspecifiedOther keratitisHerpesviral keratitis and keratoconjunctivitisKeratitis and keratoconjunctivitis in other infectious and parasitic diseases classified elsewhere
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT00912509
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT00912509 through Pure Global AI's free database. This phase not specified trial is sponsored by Price Vision Group and is currently Terminated. The study focuses on Infectious Keratitis. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.